CIC
What's Inside


College Links

 About

 Directory

 Employment

 Map/Directions

 Volunteer

Search

 

 

Make a Gift box


 

 
  Home > Current Clinical Trials > Oncology
 

Oncology

PUB/CVM/CIC/AmberLuke

Welcome to the Oncology Clinical Trials Page!

The following studies are currently recruiting patients.

Click on the study name for full information below:
 

  1. SRCBST: dose-finding for a ligand targeted toxin to treat hemangiosarcoma 
  2. Hypoxyprobe study
  3. Downregulation of Protein Kinase CK2 as Targeted Therapy for Feline Oral Squamous Cell Carcinoma  
  4. Compassionate Use of TTG100 in Canine Cancer

SRCBST: dose-finding for a ligand targeted toxin to treat hemangiosarcoma 

Current Status: Active and enrolling
Principal Investigator: Jaime Modiano, VMD, PhD
Co-Investigators: Antonella Borgatti, DVM, DACVIM; Mike Henson, DVM, PhD, DACVIM
Contacts:
Dr. Modiano, modiano@umn.edu
Amber Winter, study technician: 612-624-1352 or alwinter@umn.edu
Oncology service at 612-626-8387 (main VMC number) 

Hemangiosarcoma (HSA) is a type of sarcoma that is difficult to treat because of its aggressive behavior and rapid progression after diagnosis. We have shown that a bispecific targeted toxin (sarcoma bispecific targeted toxin, or SRCBST) is safe in other species and that it can kill hemangiosarcoma cells in the laboratory. This is a dose-finding trial to determine the safest dose of SRCBST which is still effective. Results of this study will provide information to develop a therapy for both dogs and humans with this incurable disease.

Dogs eligible for the study:

  • diagnosed with HSA
  • spleen removed by surgery either prior to study or at the Veterinary Medical Center
  • no evidence of metastasis (on chest x-ray, ultrasound and/or seen during surgery)
  • no concurrent kidney, liver or heart disease, or problems with blood clotting
  • no previous chemotherapy (prednisone is ok), cyclophosphamides, or alternative medications*

The study involves:

  • PET-CT prior to start of treatment. This imaging will allow us to look for micro-metastasis but will not exclude dogs if any are found. We will transport the dog to the Mpls campus Center for Clinical Imaging Research (CCIR), perform the PET-CT under general anesthesia, then return the dog to the VMC. CIC staff will remain with the dog throughout this procedure.
  • Day 1, 3, 6 visit the VMC for SRCBST administration and follow up blood testing
  • Day 8 recheck visit
  • Day 21 - chemotherapy begins, continues for total of 5 treatments, 3 weeks apart
  • Month 6 follow up

The study covers the costs of prescreening diagnostics, study visits day 1-8, study drug, PET-CT and blood sampling. The owner is responsible for the initial oncology exam fee. The covered costs are equivalent to approximately $3800-$9560 in value. In addition, the study covers up to $3300 of chemotherapy treatment, which will be most if not all of the cost.

*Herbal medications such as Yunnan Bai Yao will have to be stopped prior to enrollment. 

Return to top

Hypoxyprobe study 

Current Status: Active and enrolling
Principal Investigator: Sara Fritz, DVM
Contacts:
Dr. Sara Fritz: 612-626-4333 or sefritz@umn.edu
Amber Winter, study technician: 612-624-1352 or alwinter@umn.edu
Oncology service at 612-626-8387 (main VMC number)

This pilot study will use a new technique to visualize hypoxic, or low oxygen, areas of a bone biopsy taken from dogs with suspected osteosarcoma (OSA). Oxygen gradients exist in normal and tumor tissue. These gradients affect the cells at the genetic level and are important in normal and abnormal conditions. Until recently it was difficult to measure these gradients at the cellular level but Hypoxyprobe-1 (pimonidazole HCL) has made this possible. If scientists can understand these areas in tumors they may be able to develop treatments for  these tumors in the future.

We are looking for dogs scheduled to have a bone biopsy at the Veterinary Medical Center (VMC). Owners who consent to this study will bring their dog the day before the biopsy to receive one intravenous (IV) treatment of Hypoxyprobe-1. Dogs will stay overnight for observation.

The study will cover the cost of the hypoxyprobe and the overnight stay in the hospital.

Return to top

Downregulation of Protein Kinase CK2 as Targeted Therapy for Feline Oral Squamous Cell Carcinoma 

Current Status: Active and enrolling
Principal Investigator: Antonella Borgatti, DVM, DACVIM
Contacts:
Dr. Borgatti: borgatti@umn.edu
Amber Winter, study technician: 612-624-1352 or alwinter@umn.edu
Oncology service at 612-626-8387 (main VMC number) 

Feline oral squamous cell carcinoma (FOSCC) is one of the most common cancers seen in cats and it significantly impairs these cats' quality of life. This study will use gene therapy against a target that is commonly impaired in cancer, and is given in a new delivery agent (nanocapsule). The study is looking at the safety and efficacy of the new therapy in a standard dose escalation trial.

Cats eligible for the study:

  • Cats with oral squamous cell carcinoma restricted to the oral cavity and regional lymph nodes only
  • Measurable disease (>1 cm)
  • No distant metastases present based upon abdominal ultrasound and chest radiographs
  • No severe systemic disease based upon exam, bloodwork including thyroid (TT4), and urinalysis

Study procedures and schedule:

  • Initial screening (see eligible list above)
  • Day 1 biopsy of tumor and normal oral tissue
  • Monday/Thursday or Tuesday/Friday schedule of treatment, each time dosing with nanocapsules given intravenously (IV). Blood and urine tests once per week. This schedule continues for 3 weeks.
  • Final visit with biopsy, blood and urine testing

This study covers the costs of the nanocapsules injections and study procedures above (value of $2200 - $2500). The client will be responsible for the initial screening (approx. $600 - $950). 

Return to top

Compassionate Use of TTG100 in Canine Cancer

Current Status: Active and enrolling
Principal Investigator: Mike Henson, DVM, PhD, DACVIM
Contacts:
Dr. Henson: henso001@umn.edu
Amber Winter, study technician: 612-624-1352 or alwinter@umn.edu
Oncology service at 612-626-8387 (main VMC number) 

TTG100 is a new drug in a class of drugs which may be effective against a variety of types of cancer in dogs. In particular, we are seeking Bernese Mountain dogs and Golden Retrievers with histiocytic sarcoma. We may be able to treat other breeds and other cancers as well. The study involves an oral drug given at home, with five visits to the Veterinary Medical Center over a 3-4 month period.

Owners will be responsible for the costs of the visits. However, thanks to our generous donors, we can offer a $1,000 credit to owners to help with costs, paid as $500 at enrollment and $500 at the conclusion of the study. 

Return to top

For more information on cancer research at the College of Veterinary Medicine, please go to the Animal Cancer Care and Research site.

For information on the Oncology department at the Veterinary Medical Center, go here.

You may also Contact Us at the CIC.

 

 

Notice of Privacy Practices